Abiopharma

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Johnson & Johnson - Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

General Announcement: PROPOSED ACQUISITION OF STRATEGIC STAKE IN AP BIORESOURCES SDN BHD

New Form EFFECT - GENMAB A/S Filed: 2025-07-15 AccNo: 9999999995-25-002257 Size: 1 KB

New Form EFFECT - Tectonic Therapeutic, Inc. Filed: 2025-07-15 AccNo: 9999999995-25-002258 Size: 1 KB

New Form EFFECT - 60 DEGREES PHARMACEUTICALS, INC. Filed: 2025-07-15 AccNo: 9999999995-25-002259 Size: 1 KB

New Form EFFECT - BriaCell Therapeutics Corp. Filed: 2025-07-15 AccNo: 9999999995-25-002260 Size: 1 KB

New Form EFFECT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. Filed: 2025-07-15 AccNo: 9999999995-25-002256 Size: 1 KB

Zomedicas Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for Pets

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

FDA approve ANASTROZOLE

FDA approve TESTOSTERONE

FDA approve CETIRIZINE HYDROCHLORIDE